Dilip Shanghvi Net Worth (Updated 2024)

What is Dilip Shanghvi’s Net Worth?

Dilip Shanghvi, the founder of Sun Pharmaceutical Industries, has an estimated net worth of $25.7 billion. Shanghvi’s wealth primarily stems from his 54% stake in Sun Pharmaceutical Industries, a leading generic drug manufacturer with over 40 manufacturing facilities serving more than 100 countries.

In addition, he holds about 66% of Sun Pharma Advanced Research, the research and development arm of Sun Pharma, and a 13% stake in Suzlon Energy, a wind turbine maker.

Sun Pharmaceutical Industries has grown significantly under Shanghvi’s leadership, with notable acquisitions including Caraco Pharma in 1997 and Ranbaxy Laboratories in 2015, the latter making Sun Pharma the largest drug company in India and the fifth largest in the world.

Here’s the breakdown of Dilip Shanghvi’s net worth:


Dilip Shanghvi

Net Worth:

$27.0 Billion

Date of Birth:

Apr 28, 1962



If you’re curious about how we estimate a celebrity’s net worth, you can check out our methodology here.

Dilip Shanghvi

Early Life

Dilip Shanghvi was born on October 1, 1955, in Amreli, a small town in Gujarat, India. He grew up in Kolkata, where his father, Shantilal Shanghvi, ran a wholesale pharmaceutical business.

Shanghvi attended J.J. Ajmera High School and later graduated with a Bachelor of Commerce degree from the University of Calcutta. His early exposure to the pharmaceutical industry through his father’s business played a significant role in shaping his career path.

Business Career

Dilip Shanghvi’s entrepreneurial journey began in 1982 when he founded Sun Pharmaceutical Industries with a modest capital of INR 10,000. Initially, the company focused on producing a single psychiatry drug, Lithosun, in a small manufacturing unit in Vapi, Gujarat. Under Shanghvi’s leadership, Sun Pharma expanded rapidly, acquiring several companies to enhance its market presence and capabilities.

Key acquisitions include:

  • Caraco Pharma (1997): This acquisition provided Sun Pharma with a foothold in the U.S. market.
  • Taro Pharma (2007): Despite a prolonged takeover battle, this acquisition significantly boosted Sun Pharma’s global reach.
  • Ranbaxy Laboratories (2015): This $4 billion acquisition made Sun Pharma the largest pharmaceutical company in India and the fifth largest globally.

Shanghvi’s strategic vision and aggressive acquisition strategy have been pivotal in Sun Pharma’s growth. The company now operates over 40 manufacturing facilities and serves more than 100 countries, generating substantial revenue.

Personal Life

Dilip Shanghvi is married to Vibha Shanghvi, and they have two children, Aalok and Vidhi, both of whom are involved in Sun Pharmaceuticals. Despite his immense wealth and success, Shanghvi is known for his low-profile lifestyle. He is a devotee of Shrinathji and regularly visits the deity’s temple in Nathdwara, Rajasthan.

Shanghvi has also been recognized for his contributions to the pharmaceutical industry and his philanthropic efforts. He was awarded the Padma Shri, India’s fourth highest civilian honor, in 2016.

In addition, he serves on various boards and committees, including the Reserve Bank of India’s central board and the board of governors at IIT Bombay.

Leave a Comment